PALL CORPORATION

PALL CORPORATION

March 10, 2005 14:19 ET

Pall Corporation and Gambro BCT Sign Global Supply Agreement for Leukoreduction Filters


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: PALL CORPORATION

NYSE SYMBOL: PLL

MARCH 10, 2005 - 14:19 ET

Pall Corporation and Gambro BCT Sign Global Supply
Agreement for Leukoreduction Filters

EAST HILLS, N.Y.--(CCNMatthews - Mar 10, 2005) -

Pall Corporation (NYSE:PLL) today announced that it has signed a new
multi-year contract for leukocyte (white blood cell) reduction filters
with Gambro BCT, Inc. Pall will be the sole source, global provider of
leukoreduction filters for red cells, plasma and platelets for Gambro
BCT's automated blood collection and whole blood processing systems.

The new agreement through 2010 is an expansion of a five-year long
relationship between the two companies. Pall currently provides red cell
leukoreduction filters for Gambro BCT's Trima® Automated Blood
Collection System. The Trima system enables blood centers to collect
multiple component combinations of leukoreduced, ready-to-store red
cells - including double red cells - platelets and plasma, from a single
donor, in a single donation.

Gambro BCT is developing automated processing technologies for blood
centers to separate whole blood into leukoreduced components in a single
step. Blood centers generally carry out these processes manually with
time-consuming, labor-intensive steps. Automation of whole blood
processing will deliver high quality, consistent blood components, and
Pall's leukoreduction filters will be a critical element of this new
technology.

"Our relationship with Pall is mutually beneficial for all of our
stakeholders, including blood centers and the transfusion patients they
serve," says David Perez, President of Gambro BCT. "Pall's proven track
record, deep product line and innovation in developing the most advanced
leukocyte reduction technologies is an ideal fit with our automated
blood processing and collection systems today and for the future."

Allan Ross, President of Pall Medical, says, "We are pleased that Gambro
BCT recognizes the quality of our products by selecting Pall as its
exclusive supplier of leukoreduction technology. We are delivering
world-class leukoreduction filters to a worldwide leader in automated
blood collection and processing."

Pall Medical is the global leader in leukocyte reduction technologies.
The Company is currently finalizing development of its latest advance in
leukocyte reduction. The Pall Leukotrap® Affinity Prion Reduction
Filter reduces both leukocytes and prions from blood in a single step.
Prions are associated with several fatal neurodegenerative diseases
including variant Creutzfeldt-Jakob Disease (vCJD), the human form of
'mad cow disease'. Pall expects to introduce the new filter in Europe
this spring.

Gambro BCT, Inc. headquartered in Lakewood, Colorado, is a world leader
in blood bank technologies, automated blood collections and processing,
pathogen reduction techniques and valued added blood and cell-based
therapeutic services. Gambro BCT operates production facilities in the
US and the UK, and has sales in more than 90 countries. It is a wholly
owned subsidiary of Gambro AB, a global medical technology and
healthcare company.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of
filtration, separations and purification. Pall's business is organized
around two broad markets: Life Sciences and Industrial. The Company
provides leading-edge products to meet the demanding needs of customers
in biotechnology, pharmaceutical, transfusion medicine, semiconductor,
water purification, aerospace and broad industrial markets. Total
revenues for fiscal 2004 were $1.8 billion. The Company headquarters are
in East Hills, New York with extensive operations throughout the world.
Visit Pall at http://www.pall.com.

This release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. These statements are
based on current Company expectations and are subject to risks and
uncertainties which could cause actual results to differ materially.
Such risks and uncertainties include, but are not limited to:
fluctuations in foreign currency exchange rates; regulatory approval and
market acceptance of new technologies; changes in product mix and
product pricing and in interest rates and cost of raw materials; the
Company's success in enforcing its patents and protecting its
proprietary products and manufacturing techniques and its ability to
achieve the savings anticipated from its cost reduction initiatives;
global and regional economic conditions and legislative, regulatory and
political developments; and domestic and international competition in
the Company's global markets. Additional information regarding these and
other factors is available on the Web at www.pall.com and is included in
the Company's reports filed with the U.S. Securities and Exchange
Commission. Copies of such reports can be obtained, without charge, at
www.sec.gov.

Management uses certain non-GAAP measurements to assess Pall's current
and future financial performance. The non-GAAP measurements do not
replace the presentation of Pall's GAAP financial results. These
measurements provide supplemental information to assist management in
analyzing Pall's financial position and results of operations. Pall has
chosen to provide this information to facilitate meaningful comparisons
of past, present and future operating results and as a means to
emphasize the results of on-going operations.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Pall Corporation
    Patricia Iannucci, 516-801-9100
    Email: piannucci@pall.com